Breast Cancer Research and Treatment

, Volume 101, Issue 2, pp 125–134 | Cite as

Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys

  • Charles E. WoodEmail author
  • Thomas C. Register
  • Cynthia J. Lees
  • Haiying Chen
  • Sabrina Kimrey
  • J. Mark Cline
Preclinical Study


The addition of the synthetic progestin medroxyprogesterone acetate (MPA) to postmenopausal estrogen therapy significantly increases breast cancer risk. Whether this adverse effect is specific to MPA or characteristic of all progestogens is not known. The goal of this study was to compare the effects of oral estradiol (E2) given with either MPA or micronized progesterone (P4) on risk biomarkers for breast cancer in a postmenopausal primate model. For this randomized crossover trial, twenty-six ovariectomized adult female cynomolgus macaques were divided into social groups and rotated randomly through the following treatments (expressed as equivalent doses for women): (1) placebo; (2) E2 (1 mg/day); (3) E2 + P4 (200 mg/day); and (4) E2 + MPA (2.5 mg/day). Hormones were administered orally, and all animals were individually dosed. Treatments lasted two months and were separated by a one-month washout period. The main outcome measure was breast epithelial proliferation, as measured by Ki67 expression. Compared to placebo, E2 + MPA resulted in significantly greater breast proliferation in lobular (P < 0.01) and ductal (P < 0.01) epithelium, while E2 + P4 did not. Intramammary gene expression of the proliferation markers Ki67 and cyclin B1 was also higher after treatment with E2 + MPA (P < 0.01) but not E2 + P4. Both progestogens significantly attenuated E2 effects on body weight, endometrium, and the TFF1 marker of estrogen receptor activity in the breast. These findings suggest that oral micronized progesterone has a more favorable effect on risk biomarkers for postmenopausal breast cancer than medroxyprogesterone acetate.


Hormone Therapy Breast Cancer Progesterone Medroxyprogesterone Acetate Estrogen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



This work was supported by the Martin & Sharleen Cohen Foundation for Biomedical Research (JMC) and the NIH/NCRR K01-00019 (CEW). The investigators thank Dr. Martin Cohen for initiating the project. We also thank Jean Gardin, Chuck Boyd, Hermina Borgerink, Joseph Finley, Lisa O’Donnell, Gerald Perry, Maryanne Post, and Dewayne Cairnes for technical assistance and Dr. Thomas B. Clarkson for advice in planning the experiment.


  1. 1.
    Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ (1999) Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 130:545–553PubMedGoogle Scholar
  2. 2.
    Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53PubMedCrossRefGoogle Scholar
  3. 3.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J Writing Group for the Women’s Health Initiative Investigators (2002) Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712PubMedCrossRefGoogle Scholar
  5. 5.
    Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253PubMedCrossRefGoogle Scholar
  6. 6.
    Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Estrogen-progestin replacement and risk of breast cancer. JAMA 284:691–694PubMedCrossRefGoogle Scholar
  7. 7.
    Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332PubMedCrossRefGoogle Scholar
  8. 8.
    Warren MP (2004) A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 190:1141–1167PubMedCrossRefGoogle Scholar
  9. 9.
    Turgeon JL, McDonnell DP, Martin KA, Wise PM (2004) Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304:1269–1273PubMedCrossRefGoogle Scholar
  10. 10.
    Sitruk-Ware R (2004) Pharmacological profile of progestins. Maturitas 47:277–283PubMedCrossRefGoogle Scholar
  11. 11.
    Wiegratz I, Kuhl H (2004) Progestogen therapies: differences in clinical effects? Trends Endocrinol Metab 15:277–285PubMedCrossRefGoogle Scholar
  12. 12.
    Boothby LA, Doering PL, Kipersztok S (2004) Bioidentical hormone therapy: a review. Menopause 11:356–367PubMedCrossRefGoogle Scholar
  13. 13.
    Maxson WS, Hargrove JT (1985) Bioavailability of oral micronized progesterone. Fertil Steril 44:622–626PubMedGoogle Scholar
  14. 14.
    Fitzpatrick LA, Good A (1999) Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 72:389–397PubMedCrossRefGoogle Scholar
  15. 15.
    Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454PubMedCrossRefGoogle Scholar
  16. 16.
    Franke HR, Vermes I (2003) Differential effects of progestogens on breast cancer cell lines. Maturitas 46:S55–S58PubMedCrossRefGoogle Scholar
  17. 17.
    Corner GW (1923) Ovulation and menstruation in Macacus rhesus. Contrib Embryol 15:73–102Google Scholar
  18. 18.
    Gilardi KV, Shideler SE, Valverde CR, Roberts JA, Lasley BL (1997) Characterization of the onset of menopause in the rhesus macaque. Biol Reprod 57:335–340PubMedCrossRefGoogle Scholar
  19. 19.
    Magness CL, Fellin PC, Thomas MJ, Korth MJ, Agy MB, Proll SC, Fitzgibbon M, Scherer CA, Miner DG, Katze MG, Iadonato SP (2005) Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human. Genome Biol 6:R60 PubMedCrossRefGoogle Scholar
  20. 20.
    Pavlicek A, Noskov VN, Kouprina N, Barrett JC, Jurka J, Larionov V (2004) Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition. Hum Mol Genet 13:2737–2751PubMedCrossRefGoogle Scholar
  21. 21.
    Speert H (1948) The normal and experimental development of the mammary gland of the rhesus monkey with some pathologic correlations. Contrib Embryol 32:9–65Google Scholar
  22. 22.
    Tsubura A, Hatano T, Hayama S, Morii S (1991) Immunophenotypic difference of keratin expression in normal mammary glandular cells from five different species. Acta Anatomica 140:287–293PubMedCrossRefGoogle Scholar
  23. 23.
    Cline JM, Soderqvist G, von Schoultz B, Skoog L (1997) Regional distribution of proliferating cells and hormone receptors in the mammary gland of surgically postmenopausal macaques. Gynecol Obstet Invest 44:41–46PubMedCrossRefGoogle Scholar
  24. 24.
    Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B 1998 Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 48:221–229PubMedCrossRefGoogle Scholar
  25. 25.
    Wood CE, Usborne A, Tarara R, Starost MF, Hill LR, Wilkinson M, Feiste EA, Cline JM (2006) Hyperplastic and neoplastic lesions of the mammary gland in macaques. Vet Pathol (in press)Google Scholar
  26. 26.
    Wood CE, Register TC, Franke AA, Anthony MS, Cline JM (2006) Dietary Soy Isoflavones Inhibit Estrogen Effects in the Postmenopausal Breast. Cancer Res 66:1241–1249PubMedCrossRefGoogle Scholar
  27. 27.
    Lobo RA, Cassidenti DL (1992) Pharmacokinetics of oral 17 beta-estradiol. J Reprod Med 37:77–84PubMedGoogle Scholar
  28. 28.
    Veronese SM, Gambacorta M (1991) Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 95:30–34PubMedGoogle Scholar
  29. 29.
    Cline JM, Söderqvist G, von Schoultz E, Skoog L, von Schoultz B (1996) Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 174:93–100PubMedCrossRefGoogle Scholar
  30. 30.
    Cline JM, Register TC, Clarkson TB (2002) Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 9:422–429PubMedCrossRefGoogle Scholar
  31. 31.
    Clarkson TB, Appt SE, Wood CE, Cline JM (2004) Lessons to be learned from animal studies on hormones and the breast. Maturitas 49:79–89PubMedCrossRefGoogle Scholar
  32. 32.
    Ory K, Lebeau J, Levalois C, Bishay K, Fouchet P, Allemand I, Therwath A, Chevillard S (2001) Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat 68:187–198PubMedCrossRefGoogle Scholar
  33. 33.
    Nunez G, Benedict MA, Hu Y, Inohara N (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237–3245PubMedCrossRefGoogle Scholar
  34. 34.
    Berry M, Nunez AM, Chambon P (1989) Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86:1218–1222PubMedCrossRefGoogle Scholar
  35. 35.
    Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95:30–37PubMedCrossRefGoogle Scholar
  36. 36.
    Foidart JM, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, de Lignieres B (1998) Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 69:963–969PubMedCrossRefGoogle Scholar
  37. 37.
    Chang KJ, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B (1995) Influences of percutaneous administration of estradiol and progesterone of human breast epithelial cell cycle in vivo. Fertil Steril 63:785–791PubMedGoogle Scholar
  38. 38.
    Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89:1110–1116PubMedCrossRefGoogle Scholar
  39. 39.
    Schultz JR, Petz LN, Nardulli AM (2005) Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem 280:347–354PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Charles E. Wood
    • 1
    Email author
  • Thomas C. Register
    • 1
  • Cynthia J. Lees
    • 1
  • Haiying Chen
    • 2
  • Sabrina Kimrey
    • 1
  • J. Mark Cline
    • 1
  1. 1.Department of Pathology/Section on Comparative Medicine Wake Forest University School of MedicineWinston-SalemUSA
  2. 2.Department of Biostatistical SciencesWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations